189 related articles for article (PubMed ID: 24220856)
41. Restoration of miR-200c to ovarian cancer reduces tumor burden and increases sensitivity to paclitaxel.
Cittelly DM; Dimitrova I; Howe EN; Cochrane DR; Jean A; Spoelstra NS; Post MD; Lu X; Broaddus RR; Spillman MA; Richer JK
Mol Cancer Ther; 2012 Dec; 11(12):2556-65. PubMed ID: 23074172
[TBL] [Abstract][Full Text] [Related]
42. A high-throughput screen identifies miRNA inhibitors regulating lung cancer cell survival and response to paclitaxel.
Du L; Borkowski R; Zhao Z; Ma X; Yu X; Xie XJ; Pertsemlidis A
RNA Biol; 2013 Nov; 10(11):1700-13. PubMed ID: 24157646
[TBL] [Abstract][Full Text] [Related]
43. MiR-200c and HuR in ovarian cancer.
Prislei S; Martinelli E; Mariani M; Raspaglio G; Sieber S; Ferrandina G; Shahabi S; Scambia G; Ferlini C
BMC Cancer; 2013 Feb; 13():72. PubMed ID: 23394580
[TBL] [Abstract][Full Text] [Related]
44. MiR-1307 promotes ovarian cancer cell chemoresistance by targeting the ING5 expression.
Chen WT; Yang YJ; Zhang ZD; An Q; Li N; Liu W; Yang B
J Ovarian Res; 2017 Jan; 10(1):1. PubMed ID: 28086946
[TBL] [Abstract][Full Text] [Related]
45. miR-375 is upregulated in acquired paclitaxel resistance in cervical cancer.
Shen Y; Wang P; Li Y; Ye F; Wang F; Wan X; Cheng X; Lu W; Xie X
Br J Cancer; 2013 Jul; 109(1):92-9. PubMed ID: 23778521
[TBL] [Abstract][Full Text] [Related]
46. MicroRNA 130b enhances drug resistance in human ovarian cancer cells.
Zong C; Wang J; Shi TM
Tumour Biol; 2014 Dec; 35(12):12151-6. PubMed ID: 25155039
[TBL] [Abstract][Full Text] [Related]
47. [Expression of microRNA 27a and its correlation with drug resistance in human ovarian cancer A2780/Taxol cells].
Li ZM; Hu S; Xiao L; Wang J; Cai J; Yu LL; Wang ZH
Zhonghua Fu Chan Ke Za Zhi; 2010 May; 45(5):372-5. PubMed ID: 20646448
[TBL] [Abstract][Full Text] [Related]
48. Long non-coding RNA UCA1 promotes the progression of paclitaxel resistance in ovarian cancer by regulating the miR-654-5p/SIK2 axis.
Li ZY; Wang XL; Dang Y; Zhu XZ; Zhang YH; Cai BX; Zheng L
Eur Rev Med Pharmacol Sci; 2020 Jan; 24(2):591-603. PubMed ID: 32016960
[TBL] [Abstract][Full Text] [Related]
49. miR-142-5p enhances cisplatin-induced apoptosis in ovarian cancer cells by targeting multiple anti-apoptotic genes.
Li X; Chen W; Jin Y; Xue R; Su J; Mu Z; Li J; Jiang S
Biochem Pharmacol; 2019 Mar; 161():98-112. PubMed ID: 30639456
[TBL] [Abstract][Full Text] [Related]
50. miR-218 targets survivin and regulates resistance to chemotherapeutics in breast cancer.
Hu Y; Xu K; Yagüe E
Breast Cancer Res Treat; 2015 Jun; 151(2):269-80. PubMed ID: 25900794
[TBL] [Abstract][Full Text] [Related]
51. Identification of tumor suppressor miRNAs by integrative miRNA and mRNA sequencing of matched tumor-normal samples in lung adenocarcinoma.
Yu N; Yong S; Kim HK; Choi YL; Jung Y; Kim D; Seo J; Lee YE; Baek D; Lee J; Lee S; Lee JE; Kim J; Kim J; Lee S
Mol Oncol; 2019 Jun; 13(6):1356-1368. PubMed ID: 30913346
[TBL] [Abstract][Full Text] [Related]
52. Paclitaxel resistance and the role of miRNAs in prostate cancer cell lines.
Samli H; Samli M; Vatansever B; Ardicli S; Aztopal N; Dincel D; Sahin A; Balci F
World J Urol; 2019 Jun; 37(6):1117-1126. PubMed ID: 30244336
[TBL] [Abstract][Full Text] [Related]
53. Suppressive role exerted by microRNA-29b-1-5p in triple negative breast cancer through SPIN1 regulation.
Drago-Ferrante R; Pentimalli F; Carlisi D; De Blasio A; Saliba C; Baldacchino S; Degaetano J; Debono J; Caruana-Dingli G; Grech G; Scerri C; Tesoriere G; Giordano A; Vento R; Di Fiore R
Oncotarget; 2017 Apr; 8(17):28939-28958. PubMed ID: 28423652
[TBL] [Abstract][Full Text] [Related]
54. Carboplatin with Decitabine Therapy, in Recurrent Platinum Resistant Ovarian Cancer, Alters Circulating miRNAs Concentrations: A Pilot Study.
Benson EA; Skaar TC; Liu Y; Nephew KP; Matei D
PLoS One; 2015; 10(10):e0141279. PubMed ID: 26485143
[TBL] [Abstract][Full Text] [Related]
55. MiR-30a-5p Inhibits Epithelial-to-Mesenchymal Transition and Upregulates Expression of Tight Junction Protein Claudin-5 in Human Upper Tract Urothelial Carcinoma Cells.
Chung YH; Li SC; Kao YH; Luo HL; Cheng YT; Lin PR; Tai MH; Chiang PH
Int J Mol Sci; 2017 Aug; 18(8):. PubMed ID: 28829370
[TBL] [Abstract][Full Text] [Related]
56. STAT3 Mediated miR-30a-5p Inhibition Enhances Proliferation and Inhibits Apoptosis in Colorectal Cancer Cells.
Cheng CC; Yang BL; Chen WC; Ho AS; Sie ZL; Lin HC; Chang CC
Int J Mol Sci; 2020 Oct; 21(19):. PubMed ID: 33023006
[TBL] [Abstract][Full Text] [Related]
57. MiR-335-5p restores cisplatin sensitivity in ovarian cancer cells through targeting BCL2L2.
Liu R; Guo H; Lu S
Cancer Med; 2018 Sep; 7(9):4598-4609. PubMed ID: 30019389
[TBL] [Abstract][Full Text] [Related]
58. [Effect of miR-30a-5p on the proliferation, apoptosis, invasion and migration of SMCC-7721 human hepatocellular carcinoma cells].
Dai H; Kang B; Zuo D; Zuo G
Zhonghua Gan Zang Bing Za Zhi; 2014 Dec; 22(12):915-20. PubMed ID: 25654285
[TBL] [Abstract][Full Text] [Related]
59. A miRNA-200c/cathepsin L feedback loop determines paclitaxel resistance in human lung cancer A549 cells in vitro through regulating epithelial-mesenchymal transition.
Zhao YF; Han ML; Xiong YJ; Wang L; Fei Y; Shen X; Zhu Y; Liang ZQ
Acta Pharmacol Sin; 2018 Jun; 39(6):1034-1047. PubMed ID: 29219949
[TBL] [Abstract][Full Text] [Related]
60. MicroRNA Expression Profiles in Human Samples and Cell Lines Revealed Nine miRNAs Associated with Cisplatin Resistance in High-Grade Serous Ovarian Cancer.
Flores-Colón M; Rivera-Serrano M; Reyes-Burgos VG; Rolón JG; Pérez-Santiago J; Marcos-Martínez MJ; Valiyeva F; Vivas-Mejía PE
Int J Mol Sci; 2024 Mar; 25(7):. PubMed ID: 38612604
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
